Monograph Capital

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. It specializes in developing innovative therapies known as "nocions," which are designed to treat conditions resulting from neurogenic inflammation. These therapies selectively target activated nociceptors, the sensory neurons responsible for pain perception, by utilizing small molecule charged sodium channel blockers. This targeted approach aims to provide robust and sustained relief from serious conditions such as cough, itch, pain, and inflammation, addressing the limitations of traditional small molecule anesthetics.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

Odaia is a developer of an AI-powered Customer Data Platform tailored for the Life Sciences industry. The company has pioneered the integration of process mining, customer journey mapping, and artificial intelligence to provide goal-driven commercial insights and process automation. Through its predictive analytics and commercial insights platform, Odaia assists clients in facilitating personalized selling. This innovative solution enables pharmaceutical commercial teams to analyze data effectively, ensuring that therapeutics reach the patients who need them. Odaia's focus on leveraging advanced technology positions it as a leader in enhancing the efficiency and effectiveness of sales strategies within the healthcare sector.

Maxion Therapeutics is a biopharmaceutical company focused on developing innovative therapies for diseases driven by ion channels and G protein-coupled receptors (GPCRs). The company utilizes a unique drug discovery platform that integrates ion channel-modulating mini-proteins, known as knottins, derived from venom and other natural sources. By combining these knottins with antibody frameworks, Maxion aims to create long-acting, safe, and effective therapeutics that address previously inaccessible medical targets. This approach enables the potential treatment of various conditions, including chronic pain, autoimmune disorders, and heart disease, ultimately enhancing patient care through advanced drug development.

RegASK Pte. Ltd. is a RegTech company headquartered in Singapore, established in 2018. The firm specializes in developing an artificial intelligence-driven platform that assists businesses in managing regulatory compliance across various industries, including food, dietary supplements, cosmetics, personal care, and medical devices. The company's services encompass a wide range of regulatory needs, such as path-to-market, path-to-claim, product registration, and strategic guidance. RegASK's technology continuously monitors and reports updates on relevant regulations, providing clients with real-time alerts and insights into environmental, social, and governance (ESG) issues. This enables organizations to streamline their regulatory research processes, reducing time and costs while allowing them to concentrate on their core competencies.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.